Drug Profile
IT 101 - Marina Biotech
Alternative Names: IT-105; IT101Latest Information Update: 28 Oct 2019
Price :
$50
*
At a glance
- Originator IthenaPharma
- Developer Adhera Therapeutics
- Class
- Mechanism of Action Cyclo-oxygenase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Inflammation
Most Recent Events
- 28 Oct 2019 No recent reports of development identified for clinical-Phase-Unknown development in Inflammation in USA
- 16 Nov 2016 IthenaPharma has been acquired by Marina Biotech
- 13 Sep 2016 Clinical trials in Inflammation in USA (unspecified route) before September 2016